EC Number   |
Protein Variants |
Reference |
|---|
   3.4.23.15 | D226A |
inactive |
754182 |
| 3.4.23.15 | G149S/S150T |
mutant enzyme shows lower specific activities than native renin. 50% loss in specific activity with 4-(4'-(dimethylaminophenylazo))-benzoyl-gamma-aminobutyryl-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Thr-EDANS and 4-(4'-(dimethylaminophenylazo))-benzoyl-gamma-aminobutyryl-Ile-His-Pro-Phe-His-Leu-Val-Ile-His-Thr-EDANS. Mutation has no effect on substrate specificity of canine renin |
680561 |
| 3.4.23.15 | G149S/S150T/V286L |
mutant enzyme shows lower specific activities than native renin |
680561 |
| 3.4.23.15 | more |
transgenic expression in Ren2 rat results in hypertension, insulin resistance, and cardiovascular damage. Treatment of young heterozygous male Ren2 and age-matched control rats with renin inhibitor aliskiren leads to significantly increased blood pressure, NADPH oxidase activity and subunit immunostaining, 3-nitrotyrosine, perivascular fibrosis, mitochondrial content and markers of activity in Ren2 rats. Both renin inhibition and blockade of the Ang I type receptor significantly attenuate cardiac functional and structural alterations |
695467 |
| 3.4.23.15 | more |
treatment of transgenic Ren2 rat results in systemic insulin resistance with decreased skeletal muscle insulin metabolic signaling and glucose uptake. Effects are associated with increased angiotensin II, mineralocorticoid receptor, angiotensin type I receptor, oxidative stress, and reduced tyrosine insulin receptor substrate phosphorylation, protein kinase B/(Akt) phosphorylation and GLUT-4 immunostaining |
697634 |
| 3.4.23.15 | V286L |
mutant enzyme shows lower specific activities than native renin |
680561 |
